Aspira Women’s Health announces VP of Finance resignation

Aspira Women’s Health Inc. (NASDAQ:AWH), a company specializing in in vitro and in vivo diagnostic substances with annual revenue of $8.96 million, has announced the departure of James Crawford, the Vice President of Finance. Crawford informed CEO Mike Buhle of his decision to resign for personal reasons, effective April 4, 2025. According to InvestingPro data, this executive change comes as the company faces significant cash burn challenges, with a weak Financial Health Score of 1.48 out of 10.

The notification of Crawford’s resignation was made in a Form 8-K filing with the Securities and Exchange Commission on March 25, 2025, detailing the event that was reported to have occurred on March 21, 2025.

Crawford’s departure will leave a vacancy in the financial leadership team of Aspira Women’s Health, which is headquartered in Austin, Texas. The company, incorporated in Delaware and formerly known as Vermillion , Inc., Ciphergen Biosystems Inc, and Abiotic Systems, has not yet announced a successor or the plans for filling the upcoming vacancy in the finance department. With a current market capitalization of just $1.43 million and trading near its 52-week low, the company appears undervalued according to InvestingPro analysis, which identifies 17 additional key investment factors for this stock.

This executive change comes at a time when Aspira Women’s Health continues to focus on developing and providing diagnostic tests and solutions in women’s health, particularly in the areas of gynecologic disease. The company’s stock, listed on The Nasdaq Stock Market under the ticker symbol AWH, has experienced significant volatility, with a -97.35% return over the past year and current price of $0.09. Investors and analysts can access detailed financial analysis and the comprehensive Pro Research Report through InvestingPro, which provides expert insights on over 1,400 US stocks.

The information regarding this corporate change is based on the press release statement filed with the SEC and does not include any speculation on the reasons behind Crawford’s departure or the impact it may have on the company’s operations or financial performance. Aspira Women’s Health has not provided any additional comments on the resignation or their plans moving forward.

In other recent news, Aspira Women’s Health has announced several significant developments. The company has resolved a compliance issue with Nasdaq’s listing rules related to a private placement of securities, which was initially priced below market value without shareholder approval. This resolution was achieved by amending the warrants to prevent exercise until shareholder approval is obtained, bringing the company back into compliance. Additionally, Aspira has withdrawn its planned public offering, retracting its Registration Statement on Form S-1, with no specific reasons disclosed for this strategic change.

In terms of leadership changes, Aspira has appointed Michael Buhle as the new Chief Executive Officer and James Crawford as the Vice President of Finance. Dr. Sandra Milligan will step down as President for personal reasons, with her responsibilities being taken over by Jamie Sullivan and Todd Pappas. Ellen Beausang has also been appointed as a new board member, bringing over 25 years of experience in the pharmaceutical and diagnostic industry. Furthermore, the company announced the resignation of board member Celeste Fralick, effective March 31, 2025, for personal reasons, with no successor announced yet. These updates underscore Aspira’s ongoing efforts to adapt and grow in the competitive healthcare diagnostics sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.